Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study

Purpose The VICTOR-1 study demonstrated that the all-oral metronomic combination of vinorelbine and capecitabine is highly active and well tolerated in hormone receptor-positive/HER2-negative patients. The VICTOR-2 study was designed to confirm these results. Methods Patients received mVNR 40 mg thr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2016-12, Vol.160 (3), p.501-509
Hauptverfasser:	Cazzaniga, M. E., Cortesi, L., Ferzi, A., Scaltriti, L., Cicchiello, F., Ciccarese, M., Della Torre, S., Villa, F., Giordano, M., Verusio, C., Nicolini, M., Gambaro, A. R., Zanlorenzi, L., Biraghi, E., Legramandi, L., Rulli, E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Metronomic Administration, Oral Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - mortality Breast Neoplasms - pathology Cancer research Cancer therapies Capecitabine - administration & dosage Clinical Trial Female Humans Medicine Medicine & Public Health Middle Aged Neoplasm Metastasis Neoplasm Staging Oncology Receptor, ErbB-2 - metabolism Retreatment Treatment Outcome Vinblastine - administration & dosage Vinblastine - analogs & derivatives
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!